动脉瘤性蛛网膜下腔出血后早期静脉米力农治疗脑血管痉挛或迟发性脑缺血的效果
该回顾性研究纳入2017至2022年连续aSAH患者336例,其中130例(39%)发生CVS或DCI,73例接受静脉米力农、57例未接受。米力农组20%需血管升压药 vs 非米力农组84%(p<0.01),血管内治疗31% vs 56%(p=0.02);症状性患者中59%在米力农启动后症状改善。单因素分析米力农与良好预后可能相关(OR 2.12,95%CI 0.97-4.63,p=0.06),倾向性评分匹配分析证实相关(系数0.30,标准误0.13,95%CI 0.05-0.55,p=0.02)。作者结论认为早期静脉米力农改善结局并减少其他治疗使用,但结果需大规模临床试验证实。
要点
- 336例aSAH中130例(39%)发生CVS或DCI,其中73例接受早期静脉米力农、57例未接受。
- 症状性CVS或DCI患者中,59%在启动米力农后症状改善。
- 米力农组需血管升压药20% vs 非米力农组84%(p<0.01),需血管内治疗31% vs 56%(p=0.02)。
- 倾向性评分匹配分析显示米力农与6个月良好预后相关(系数0.30,95%CI 0.05-0.55,p=0.02)。
- 单因素分析米力农与良好预后的关联未达统计学显著(OR 2.12,95%CI 0.97-4.63,p=0.06)。
适用人群与场景
- 2017至2022年连续收治的动脉瘤性蛛网膜下腔出血(aSAH)患者,共336例。
- 其中130例(39%)发生脑血管痉挛(CVS)或迟发性脑缺血(DCI),为接受或不接受静脉米力农比较的人群。
处置流程与药物剂量
- 早期静脉米力农作为CVS或DCI的一线治疗;给药途径为静脉,原文未报告具体剂量、频次与疗程。
研究设计与关键结果
- 回顾性研究,纳入2017至2022年连续aSAH患者336例,其中130例(39%)发生CVS或DCI;73例接受静脉米力农,57例未接受。
- 症状性患者中59%在启动米力农后症状改善。
- 米力农组20%需血管升压药 vs 非米力农组84%(p<0.01);米力农组31%接受血管内治疗 vs 非米力农组56%(p=0.02)。
- 单因素分析:米力农与良好预后可能相关(OR 2.12,95%CI 0.97-4.63,p=0.06)。
- 倾向性评分匹配分析:米力农与良好预后相关(系数0.30,标准误0.13,95%CI 0.05-0.55,p=0.02)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:存在若干方案偏离、药物效应记录不完整、CVS缓解评估不一致。
- 作者结论:结果需在按临床严重程度、指征和优化方案分层的 large clinical trial 中证实。
对床旁实践的改变
- 作者认为早期静脉米力农治疗对aSAH合并CVS或DCI患者有若干潜在获益:接受米力农者结局更好,且更少需要血管升压药或血管内治疗。
- 作者结论:早期静脉米力农改善结局并减少用于治疗CVS和DCI的其他治疗;这些结果需在大规模临床试验中按临床严重程度、指征和优化方案分层进一步证实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This study assessed the effect of intravenous (IV) milrinone as first-line therapy for cerebral vasospasm (CVS) or delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH).
METHODS: A retrospective study was performed on consecutive patients with aSAH from 2017 to 2022. We assessed the association of IV milrinone treatment with outcomes graded with modified Rankin Scale score at 6 months. We compared the use of alternative therapies for CVS or DCI between patients who received IV milrinone and those who did not. All statistical analyses were performed using STATA 18.0 (StataCorp, College Station, TX).
RESULTS: Of 336 patients, 130 (39%) developed CVS or DCI. Seventy-three patients received IV milrinone and 57 patients did not. Among symptomatic patients, 59% showed improvement in symptoms after milrinone was started. Twenty percent of patients in the milrinone group required vasopressor therapy, whereas 84% of patients were treated with vasopressors in the nonmilrinone group (p < 0.01). Thirty one percent of patients receiving milrinone and 56% of patients in the non-milrinone group received endovascular therapy (p = 0.02). Univariate analysis showed milrinone was likely associated with good outcome (odds ratio [OR] 2.12 [95% confidence interval [CI] 0.97-4.63]; p = 0.06). Propensity score matching analysis confirmed an association between milrinone and good outcome (coefficient 0.30, standard error 0.13 [95% confidence interval [CI] 0.05-0.55]; p = 0.02).
CONCLUSIONS: Our study showed several potential benefits of early IV milrinone therapy for patients with aSAH with CVS or DCI. Patients who received IV milrinone had better outcome and required vasopressor or endovascular therapy less often. Limitations of the study included several protocol deviations, incomplete documentation of drug effect, and inconsistent assessment of CVS resolution. Early IV milrinone improved outcomes and reduced the use of other therapies to treat CVS and DCI. These results need confirmation in a large clinical trial with stratification of patients by clinical severity, indication, and optimized protocols.
参考来源
- Baang HY, Reynolds AS, Dangayach NS, et al. Treatment Effect of Early Intravenous Milrinone for Cerebral Vasospasm or Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2025. PMID: 40329063. doi:10.1007/s12028-025-02260-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。